Trial Profile

Phase 1b/2a human study of SANA-013 for major depressive disorder

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 25 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SANA-013 (Primary)
Indications Major depressive disorder
Focus Adverse reactions

Most Recent Events

25 Apr 2022 New trial record
18 Apr 2022 According to a Wesana Health media release, the company expect to initiate this study in H1 2023.
18 Apr 2022 According to a Wesana Health media release, the company is proceeding on a non-brokered private placement financing for gross proceeds of up to USD$3,000,000 and the company intends to use the proceeds from the Placement towards initiating this study.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com